期刊文献+

2012年EASL-EORTC《肝细胞癌临床管理指南》简介 被引量:57

Brief introduction to 2012 EASL-EORTC Clinical Practice Guidelines on the management of hepatocellular carcinoma
下载PDF
导出
摘要 欧洲肝脏研究学会和欧洲癌症研究治疗组织于2011年底首次联合颁布了《肝细胞癌临床管理指南》,对肝细胞癌的监测、诊断、分期系统、分子分类和治疗策略提出建议,旨在根据循证医学证据为医生、患者、保健人员和政策制定者提供实践指导。 EASL-EORTC Clinical Practice Guidelines on the management of hepatocellular carcinoma (HCC) developed by European Association for the Study of the Liver and European Organisation for Research and Treatment of Cancer at the end of 2011 gives advice for the surveillance, diagnosis, staging system, molecular classification and therapeutic strategies for HCC patients in order to provide practical guidence for physicians, patients, health-care providers and health-policy makers according to evidence-based medicine.
出处 《传染病信息》 2012年第5期264-268,共5页 Infectious Disease Information
关键词 肝细胞 指南 治疗学 carcinoma, hepatocellular guidebooks therapeutics
  • 相关文献

参考文献27

  • 1Bruix J, Sherman M, Llovet JM, et ol. Clinical management of he- patocellular carcinoma. Conclusions of the Bareelona-2000 EASL conference. European Association for the Study of the Liver[J]. J Hepatol, 2001, 35(3):421-430.
  • 2National Cancer Institute. Levels of evidence for adult and pedi- atric cancer treatment studies (PDQ?)[EB/0L]. [2012-07-12]. http:// www.cancer.gov/cancertopics/pdq/levels-evidence-aduh-treatment/ HealthProfessional/page 1.
  • 3European Association for the study of the liver; European Organi- sation for research and treatment of cancer. EASL-EORTC clini- cal practice guidelines: management of hepatoeellular carcinoma [J]. J Hepatol, 2012, 56(4):908-943.
  • 4Singal AG, Volk ML, Jensen D, eta/. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus[J ]. Clin Gastroenteml Hepatol, 2010, 8(3):280-288.
  • 5Lok AS, Seeff LB, Morgan TR, eta]. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related ad- vanced liver disease[J]. Gastroenterology, 2009, 136(1):138-148.
  • 6Marrero JA, Su GL, Wei W, et ol. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chro- nic liver disease in American patients[J]. Hepatology, 2003, 37(5): 1114-1121.
  • 7Bruix J, Sherman M. Management of hepatocellular carcinoma[J]. Hepatology, 2005, 42(5):1208-1236.
  • 8Bruix J, Sherman M. Management of hepatocellular carcinoma: an update[J]. Hepatology, 2011, 53(3):1020-1022.
  • 9International Consensus Group for Hepatocellular Neoplasia. Pa- thologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia[J]. He patology, 2009, 49(2):658-664.
  • 10Llovet JM, Chen Y, Wurmbach E, eta/. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcino- ma in HCV cirrhosis[J]. Gastroenterology, 2006, 131(6):1758-1767.

二级参考文献2

共引文献66

同被引文献268

引证文献57

二级引证文献300

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部